Sanofi Consumer Healthcare India (NSE:SANOFICONR) Notes Receivable: ₹0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:SANOFICONR Sanofi Consumer Healthcare India Ltd NSE:SANOFICONR
21 GF Score
Price ₹4,523.60
! 2 Warning Signs
View Full Analysis

What is Sanofi Consumer Healthcare India Notes Receivable?

Sanofi Consumer Healthcare India NSE:SANOFICONR -0.77% 21 Notes Receivable is ₹0 Mil as of Mar. 2026. GuruFocus rates NSE:SANOFICONR with a GF Score™ of 21/100. The stock has 2 warning signs investors should review.

Sanofi Consumer Healthcare India's Notes Receivable for the quarter that ended in Mar. 2026 was ₹0 Mil.

Sanofi Consumer Healthcare India Notes Receivable Related Terms

Sanofi Consumer Healthcare India Notes Receivable Historical Data

* Premium members only.

The historical data trend for Sanofi Consumer Healthcare India's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sanofi Consumer Healthcare India Notes Receivable Chart

Sanofi Consumer Healthcare India Annual Data
Trend Dec23 Dec24 Dec25
Notes Receivable
0.00 0.00 0.00

Sanofi Consumer Healthcare India Quarterly Data
Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:SANOFICONR
21GF Score
Sanofi Consumer Healthcare India Ltd NSE:SANOFICONR
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sanofi Consumer Healthcare India Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of ₹0 Mil mean?
Sanofi Consumer Healthcare India (NSE:SANOFICONR) has a Notes Receivable of ₹0 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Sanofi Consumer Healthcare India and its competitors.
Is Sanofi Consumer Healthcare India's Notes Receivable too high?
Sanofi Consumer Healthcare India's current Notes Receivable is ₹0 Mil. Overall, Sanofi Consumer Healthcare India has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Sanofi Consumer Healthcare India's Notes Receivable compare to LLY and JNJ?
Sanofi Consumer Healthcare India's Notes Receivable of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Drug Manufacturers company?
A good Notes Receivable depends on the Drug Manufacturers industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on Sanofi Consumer Healthcare India and its competitors. Sanofi Consumer Healthcare India's current Notes Receivable is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sanofi Consumer Healthcare India stock overvalued right now?
Sanofi Consumer Healthcare India (NSE:SANOFICONR) has a current Notes Receivable of ₹0 Mil. The current Notes Receivable is ₹0 Mil. Sanofi Consumer Healthcare India's overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For Sanofi Consumer Healthcare India (NSE:SANOFICONR), the current Notes Receivable is ₹0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sanofi Consumer Healthcare India Business Description

Other Exchanges 544250:India
Address Pirojshanagar, Eastern Express Highway, Unit 1104, 11th Floor, Godrej Two, Vikhroli East, Mumbai, MH, IND, 400079
Sanofi Consumer Healthcare India Ltd is mainly engaged in the business of manufacturing and trading of drugs and pharmaceutical products. The Company also has various independent contract/third-party manufacturers based across the country and provides business support services to its group entity in India. Its products include Allergy Relief (Allegra), Pain Care (Combiflam), and Physical Wellness (DePURA). The Company sells its products in India through independent distributors and outside India. Its operations are limited to one segment, namely Pharmaceutical Business. The Company operates in India, which generates the maximum revenue, and Outside India.
21GF Score

Get the complete analysis for NSE:SANOFICONR

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹4,523.60
Price